Protection against kainate neurotoxicity by pyrrolidine dithiocarbamate
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin E.-J. | - |
dc.contributor.author | Jhoo J.H. | - |
dc.contributor.author | Kim W.-K. | - |
dc.contributor.author | Jhoo W.K. | - |
dc.contributor.author | Lee C. | - |
dc.contributor.author | Jung B.D. | - |
dc.contributor.author | Kim H.-C. | - |
dc.date.available | 2020-11-03T17:51:30Z | - |
dc.date.issued | 2004 | - |
dc.identifier.issn | 0305-1870 | - |
dc.identifier.issn | 1440-1681 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/20838 | - |
dc.description.abstract | 1. The effect of pyrrolidine dithiocarbamate (PDTC) on kainate (KA)-induced neurotoxicity was examined in Sprague-Dawley rats. 2. At 10 mg/kg, i.p., KA produced seizures accompanied by neuronal loss in the hippocampus and increased levels of malondialdehyde (MDA) and protein carbonyl. 3. Pretreatment with PDTC (100 or 200 mg/kg, p.o., every 12 h x5) blocked KA-induced neurotoxicities (seizures, increases in MDA and protein carbonyl and neuronal losses) in a dose-dependent manner. These effects were counteracted by the adenosine A 1 receptor antagonist 8-cyclopentyl-1,3-dimetliylxanthine (25 or 50 μg/kg, i.p.), but not by the A2A receptor antagonist 1,3,7-trimethyl-8-(3-chlorostyryl)xanthine (0.5 or 1 mg/kg, i.p.) or the A 2B receptor antagonist alloxazine (1.5 or 3.0 mg/kg, i.p.). 4. Our results suggest that the anticonvulsant and neuroprotective effects of PDTC are mediated, at least in part, via adenosine A1 receptor stimulation. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Protection against kainate neurotoxicity by pyrrolidine dithiocarbamate | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/j.1440-1681.2004.03990.x | - |
dc.identifier.scopusid | 2-s2.0-3042624969 | - |
dc.identifier.bibliographicCitation | Clinical and Experimental Pharmacology and Physiology, v.31, no.5-6, pp 320 - 326 | - |
dc.citation.title | Clinical and Experimental Pharmacology and Physiology | - |
dc.citation.volume | 31 | - |
dc.citation.number | 5-6 | - |
dc.citation.startPage | 320 | - |
dc.citation.endPage | 326 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | 8 (3 chlorostyryl)caffeine | - |
dc.subject.keywordPlus | 8 cyclopentyltheophylline | - |
dc.subject.keywordPlus | adenosine A1 receptor | - |
dc.subject.keywordPlus | adenosine A1 receptor antagonist | - |
dc.subject.keywordPlus | adenosine A2 receptor antagonist | - |
dc.subject.keywordPlus | adenosine A2a receptor antagonist | - |
dc.subject.keywordPlus | adenosine A2b receptor antagonist | - |
dc.subject.keywordPlus | alloxazine | - |
dc.subject.keywordPlus | anticonvulsive agent | - |
dc.subject.keywordPlus | kainic acid | - |
dc.subject.keywordPlus | malonaldehyde | - |
dc.subject.keywordPlus | protein | - |
dc.subject.keywordPlus | pyrrolidine dithiocarbamate | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | animal cell | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal model | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | brain nerve cell | - |
dc.subject.keywordPlus | cell loss | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | dose response | - |
dc.subject.keywordPlus | dose time effect relation | - |
dc.subject.keywordPlus | drug effect | - |
dc.subject.keywordPlus | drug screening | - |
dc.subject.keywordPlus | hippocampus | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | neuroprotection | - |
dc.subject.keywordPlus | neurotoxicity | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | rat | - |
dc.subject.keywordPlus | seizure | - |
dc.subject.keywordPlus | stimulation | - |
dc.subject.keywordPlus | time | - |
dc.subject.keywordPlus | Animals | - |
dc.subject.keywordPlus | Dose-Response Relationship, Drug | - |
dc.subject.keywordPlus | Excitatory Amino Acid Antagonists | - |
dc.subject.keywordPlus | Hippocampus | - |
dc.subject.keywordPlus | Kainic Acid | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Neuroprotective Agents | - |
dc.subject.keywordPlus | Pyrrolidines | - |
dc.subject.keywordPlus | Rats | - |
dc.subject.keywordPlus | Rats, Sprague-Dawley | - |
dc.subject.keywordPlus | Seizures | - |
dc.subject.keywordPlus | Thiocarbamates | - |
dc.subject.keywordAuthor | Adenosine A1 receptor | - |
dc.subject.keywordAuthor | Anti-oxidant | - |
dc.subject.keywordAuthor | Anticonvulsant effects | - |
dc.subject.keywordAuthor | Hippocampus | - |
dc.subject.keywordAuthor | Kainic acid | - |
dc.subject.keywordAuthor | Malondialdehyde | - |
dc.subject.keywordAuthor | Neuroprotective effects | - |
dc.subject.keywordAuthor | Protein carbonyl | - |
dc.subject.keywordAuthor | Pyrrolidine dithiocarbamate | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.